Search
Denali Therapeutics Inc
DNLIAdd to Watchlist
19.840USD
-0.160-0.80%
Market hours 10/05, 09:55（ET）
3.15BMarket Cap
LossP/E TTM
Denali Therapeutics Inc (DNLI) Stock Price Target & Forecast
Analyst Rating
Based on 20 analysts giving stock ratings to Denali Therapeutics Inc in the past month.
Buy
9 Strong Buy
10 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
36.533USD+82.67%
DNLI Analyst Recommendation Trends
In the current month, DNLI has received 10 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. DNLI average Analyst price target in the last month is 36.533.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
9
9
9
9
9
9
9
9
10
10
9
9
9
9
9
9
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
20
20
19
19
19
18
18
18
DNLI Analyst Rating for Peer Comparison
Updated: Oct 4, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
13
3
0
0
26
IQVIA Holdings Inc
IQV
7
12
6
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Biontech SE
BNTX
4
12
6
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, DNLI EPS is projected to reach -0.536 in FY2026Q3, following reported EPS of -0.681 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.74
-0.73
-0.66
-0.54
-0.63
Actual
-0.73
-0.69
-0.68
--
--
Surprise
+1.56%
+5.20%
-3.69%
--
--
FAQs
What is Denali Therapeutics Inc's expected revenue for the next quarter?
Denali Therapeutics Inc's expected revenue is 14.61M.
What is Denali Therapeutics Inc's price target?
Analysts forecast that Denali Therapeutics Inc's price target is USD 36.53, with the highest forecast at USD 42.00 and the lowest forecast at USD 27.00.
How have Denali Therapeutics IncDNLI's recent earnings per share performed?
The market expectation was USD -0.68, while Denali Therapeutics IncDNLI's earnings per share (EPS) for the previous quarter was USD -0.69. EPS for the next quarter is expected at USD -0.54.
What is the analyst rating for Denali Therapeutics Inc?
Based on the ratings of Denali Therapeutics Inc's stock from 20 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.